Search
for
Sort by
Research 61–90 of 1000+
- What do we know about phytotherapy of benign prostatic hyperplasia?
- Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
- Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families
- NonClassic Congenital Adrenal Hyperplasia
- Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): An update
- Nonclassic adrenal hyperplasia
- Herbs for Benign Prostatic Hyperplasia
- Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
- Nonclassic Congenital Adrenal Hyperplasia
- Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
- Non-classic congenital adrenal hyperplasia
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Leydig Cell Hyperplasia and Adenomas in Mice Treated with Finasteride, a 5α-Reductase Inhibitor: A Possible Mechanism
- Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review
- Localized syringolymphoid hyperplasia with alopecia and anhidrosis
- Becker's nevus associated with chromosomal mosaicism and congenital adrenal hyperplasia
- Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
- Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Nonclassic congenital adrenal hyperplasia
- Baldness, benign prostate hyperplasia, prostate cancer and androgen levels
- A new compound heterozygous frameshift mutation in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene causes salt-wasting 3 beta-HSD deficiency congenital adrenal hyperplasia.
- Androgenetic alopecia as an early marker of benign prostatic hyperplasia
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia
- Congenital adrenal hyperplasia
- The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis
- Dutasteride for the treatment of benign prostatic hyperplasia
- Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats
- Merkel Cells in Hyperplastic and Neoplastic Lesions of the Skin